Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus.
At Northwestern University, a phase I/II trial of hematopoietic stem cell transplant (HSCT) for systemic lupus erythematosus (SLE) has shown promising results. A phase III HSCT trial is being developed to confirm efficacy of HSCT vs continuing the currently accepted standard of care, intravenous pulse cyclophosphamide.
Burt
R K
RK
Northwestern University Medical Center, Chicago, IL 60611, USA.
Marmont
A
A
Arnold
R
R
Heipe
F
F
Firestein
G S
GS
Carrier
E
E
Hahn
B
B
Barr
W
W
Oyama
Y
Y
Snowden
J
J
Kalunian
K
K
Traynor
A
A
D002985:Clinical Protocols; D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000401:mortality / Q000628:therapy*; D012720:Severity of Illness Index; D019172:Transplantation Conditioning / Q000379:methods